Pre-made Epratuzumab benchmark antibody ( Whole mAb, anti-CD22 therapeutic antibody, Anti-SIGLEC2/SIGLEC-2 Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Epratuzumab biosimilar, Whole mAb, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE).
| Products Name (INN Index) | Pre-Made Epratuzumab biosimilar, Whole mAb, Anti-CD22 Antibody: Anti-SIGLEC2/SIGLEC-2 therapeutic antibody |
|---|---|
| INN Name | Epratuzumab |
| Target | CD22 |
| Format | Whole mAb |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | 5vkk:AB:HL/5vl3:EF:AB:HL:CD |
| 95-98% SI Structure | None |
| Year Proposed | 1999 |
| Year Recommended | 2000 |
| Companies | Charite – Universitatsmedizin Berlin,Children's Oncology Group,Immunomedics,National Cancer Institute (USA),UCB |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Precursor cell lymphoblastic leukaemia-lymphoma,Systemic lupus erythematosus,Non-Hodgkin's lymphoma,Cachexia |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD22 |
| Package |
